Table 4.

Predictors of CIMIDx use of 150 women with breast cancer.

Stages		Category	Odds ratio	95% confidence interval	Significance (P)a
Age (years)			1.93	0.51-7.34	.89
Time since diagnosis (years)			0.19	0.07-0.53	.89
Annual household income (INR)
		<1,00,000	1.00
		1,00,000-2,70,000	2.44	0.19-31.53	.48
		>2,70,000	0.89	0.18-4.36	.89
Education
		Grades <12	1.00
		Grades 13-15	1.05	0.16-6.92	.96
		Grades >15	0.92	0.34-2.45	.86
Stage
	Normal	Normal breast issue	1.00
	Benign
		Fibrocystic disease	0.5	0.01-19.56	.71
		Fibroadenoma	1.5	0.09-25.39	.78
		Atypical ductal hyperplasia	0.5	0.01-19.56	.71
		Benign lesion, other	-	-	.39
	Malignant
		DCISb, grade I	1.00
		DCIS grade II and III	0.48	0.07-3.37	.45
		IDCc	1.33	0.32-5.59	.69
		ILCd	0.88	0.10-6.78	.86
		ILC and IDC	0.5	0.01-19.56	.71
		Malignant lesion, other	-	-	.39

^aFrom interviews at various medical colleges and hospitals in Chennai, Tamil Nadu, India, May 2013 to April 2014, regarding the cloud-based system support intelligent medical image diagnosis prototype used for breast health issues, the P values were calculated with t tests for the means, and the Pearson chi-Square tests for the percentages.

^bDCIS: ductal carcinoma in situ

^cIDC: invasive ductal cancer

^dILC: invasive lobular cancer